TICKERNERD
Menu
ANROANROHealthcare · Biotechnology

ANRO Stock Forecast: Alto Neuroscience, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$32
+1.01% on the day

The 11 Wall Street analysts covering Alto Neuroscience, Inc. hold a median 12-month price target of $37 — +15.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 10 Sept 2026 — in the upper half.

Market cap
$1.3B
Ticker Nerd rank
60 / 100
Median analyst target
$37
Analysts covering
11
Revenue$0.0
Operating income−$29.1M
Net income−$27.6M
Free cash flow−$19.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.1%
1M
+11.2%
YTD
+79.8%
1Y
+714.2%
From 52W high
−12.7%
From 52W low
+788.9%
$4
$37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANRO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alto Neuroscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
60 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Value
66
Accruals
57
Revisions
57
Issuance
53
Quality
45
Size
42
Growth
36
Volatility
33

Momentum (99): The shares have been drifting up relative to others.

Volatility (33): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANRO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANRO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26ANROHigh $55Median $37Low $26

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
10 Buy1 Hold0 Sell
Low $26Median $37High $55

The green dot is the last close — the median target sits +15.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
17 Aug 2026HC Wainwright & Co.MaintainsBuy$50 → $55
13 Aug 2026BTIGMaintainsBuy$28 → $37
13 Aug 2026WedbushMaintainsNeutral$24 → $26
18 May 2026BairdMaintainsOutperform$38 → $36
18 May 2026BairdMaintainsOutperform—
14 May 2026WedbushMaintainsNeutral$21 → $24
14 May 2026WedbushMaintainsNeutral—
11 May 2026HC Wainwright & Co.ReiteratesBuy$50
11 May 2026HC Wainwright & Co.ReiteratesBuy—
11 May 2026HC Wainwright& Co.ReiteratesBuy—
22 Apr 2026Chardan CapitalMaintainsBuy—
2 Apr 2026BairdMaintainsOutperform—
2 Apr 2026Chardan CapitalMaintainsBuy—
2 Apr 2026HC Wainwright & Co.ReiteratesBuy—
2 Apr 2026Jones TradingMaintainsBuy—
2 Apr 2026WedbushMaintainsNeutral—
18 Mar 2026BairdMaintainsOutperform—
17 Mar 2026Chardan CapitalMaintainsBuy—
17 Mar 2026WedbushMaintainsNeutral—
17 Feb 2026BTIGMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANRO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ANRO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Alto Neuroscience, Inc. returned +714.2% against +17.5% for the S&P 500, dividends included.

ANRO vs S&P 500, last 12 monthsTotal return, rebased to 100
02004006008001,000Oct 25Jan 26Apr 26Jul 26ANROS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANRO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Alto Neuroscience, Inc. (ANRO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−14.6×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
5.1×

Cheaper than 18% of US stocks

EV / EBITDA
−11.8×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−49.2%

Higher than 21% of US stocks

Return on assets
−26.8%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alto Neuroscience, Inc. (ANRO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alto Neuroscience, Inc. has a market value of $1.3B and an enterprise value of $1.0B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$84.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$68.8M, after $556K of capital spending.

  • Shares outstanding: 35.1M.

  • Trailing P/E: −14.6×; forward P/E: −9.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Alto Neuroscience, Inc. employs 68 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

ANRO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANROAlto Neuroscience, Inc.$1.3B
60
SPTXSeaport Therapeutics, Inc.$1.2B
2
JBIOJade Biosciences, Inc.$1.2B
28
REPLReplimune Group, Inc.$1.2B
34
ORICOric Pharmaceuticals, Inc.$1.2B
47
GLUEMonte Rosa Therapeutics, Inc.$1.2B
64
ALMSAlumis, Inc.$1.3B
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alto Neuroscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANRO news & analysis

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Business Wire · 9 Sept 2026neutral

Alto Neuroscience announced that members of its management team will participate in the H.C. Wainwright 28th Annual Global Healthcare Conference, scheduled for September 14-16, 2026, featuring a fireside chat and one-on-one meetings.

Why it matters — ANRO watchers would care because the company's participation in investor conferences provides an opportunity for management to present its clinical-stage precision medicine programs to the investment community.

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Business Wire · 27 Aug 2026neutral

Alto Neuroscience announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. Smith will continue to lead the finance function and oversee corporate strategy and business development, reporting to founder and CEO Amit Etkin.

Why it matters — This leadership promotion signals continued stability in Alto's finance and corporate strategy functions as the clinical-stage company advances its pipeline.

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Business Wire · 12 Aug 2026positive

Alto Neuroscience reported its financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. The company noted that the second quarter strengthened the case for ALTO-207 and management's conviction in its opportunity.

Why it matters — ANRO watchers would care because the update reinforces management confidence in lead candidate ALTO-207 and signals continued pipeline progress for a clinical-stage neuropsychiatric precision-medicine company.

Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications

Seeking Alpha · 3 Aug 2026positive

A Seeking Alpha article highlights Alto Neuroscience's ALTO-207, a pramipexole/ondansetron combination for treatment-resistant depression, with phase 2b topline data expected in 2H 2027 and possible phase 3 initiation by early 2027. The piece notes the company's strong cash reserves and diversified, biomarker-driven pipeline, even after ALTO-100's phase 2b failure in MDD, as supporting factors for its positive rating on the stock.

Why it matters — ANRO watchers would care because the ALTO-207 timeline and pipeline breadth are central to the company's outlook after the ALTO-100 setback.

FAQ

Frequently asked questions about ANRO stock

What is the ANRO stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Alto Neuroscience, Inc. have a median 12-month price target of $37, with estimates ranging from $26 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANRO stock a buy right now?

Of the 11 analysts covering Alto Neuroscience, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alto Neuroscience, Inc. 60 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANRO?

As at 10 Sept 2026, Alto Neuroscience, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will ANRO stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +15.6% from the last close, and Ticker Nerd's factor model ranks Alto Neuroscience, Inc. 60 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANRO stock forecast for 2030?

No analyst covering Alto Neuroscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $55 over the next 12 months.

How has ANRO stock performed over the past year?

Alto Neuroscience, Inc. returned +714.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alto Neuroscience, Inc. do?

Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders.

What is the latest news on ANRO?

The most recent item we track (Business Wire, 9 Sept 2026): "Alto Neuroscience Announces Participation in Upcoming Investor Conferences". Alto Neuroscience announced that members of its management team will participate in the H.C. Wainwright 28th Annual Global Healthcare Conference, scheduled for September 14-16, 2026, featuring a fireside chat and one-on-one meetings.

Company

About Alto Neuroscience, Inc.

Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders. Alto Neuroscience applies its Precision Psychiatry Platform to analyze brain biomarkers, EEG activity, neurocognitive assessments, wearable data, and other patient-specific measures to help match therapies with the people most likely to benefit. Its current pipeline includes drug candidates targeting bipolar depression, major depressive disorder, treatment-resistant depression, schizophrenia, and related cognitive and mood disorders. The company is centered on personalized psychiatry, using biology-driven research to support the development of novel psychiatric treatments. Alto Neuroscience is headquartered in Mountain View, California, and its work today is concentrated on advancing clinical-stage programs for mental health conditions through biomarker-guided drug development.

CEO Dr. Amit Etkin M.D., Ph.D. · 68 employees · United States · https://www.altoneuroscience.com